- ✓Control-IQ users gained nearly 1.6 extra quality-adjusted life years versus injections or standard pump therapy
- ✓Cost per quality year gained (€21,111) fell well below the €30,000–€50,000 value threshold used by health economists
- ✓Patients reported significantly less fear of hypoglycemia, reflecting real improvement in daily quality of life
| Journal | Diabetes technology & therapeutics |
| Year | 2026 |
| Authors | De Meulemeester, Fiorentino, Picado |
| PMID | 41468104 |
What Was Studied — and Why It Matters
Researchers in Belgium wanted to know whether the t:slim X2 insulin pump with Control-IQ technology is worth the extra cost compared to traditional insulin management. Control-IQ is an automated insulin delivery (AID) system — sometimes called a "closed-loop" or "artificial pancreas" system — that uses a continuous glucose monitor (CGM) to automatically adjust insulin doses around the clock.
The study looked at adults with Type 1 diabetes and asked a straightforward question: does the better blood sugar control you get from Control-IQ translate into enough health benefit to justify its price tag?
How the Study Worked
Scientists used a well-established computer model — the IQVIA CORE Diabetes Model — to simulate what happens to patients over a lifetime. They fed it real-world data from the Belgian INRANGE study, which tracked actual patients using Control-IQ. Costs included the devices themselves, managing long-term complications like kidney disease or vision loss, and emergency care for severe low blood sugar episodes. They compared three groups:
- Control-IQ pump + CGM
- Multiple daily injections (MDI) + CGM
- Standard insulin pump + CGM
What They Found
The results were striking. People using Control-IQ gained an average of 1.58 extra quality-adjusted life years (QALYs) — a measure that combines both length and quality of life — compared to injections or a standard pump with CGM. Yes, Control-IQ costs more upfront (about €193,000 over a lifetime versus €160,000), but the cost per quality year gained came to roughly €21,111 — well below the €30,000–€50,000 threshold that health economists typically consider good value.
Importantly, the study also counted something often overlooked: patients using Control-IQ reported significantly less fear of hypoglycemia (dangerous low blood sugar). Living with less anxiety about lows is a real, measurable improvement in daily life.
What This Means for Real Patients
If you or a loved one has Type 1 diabetes, this research adds to a growing body of evidence that AID systems like Control-IQ don't just improve blood sugar numbers — they improve life. Fewer complications over decades means fewer hospitalizations, less suffering, and more years living well.
For those already using a CGM, upgrading to an automated pump system may be the logical next step. Managing the supplies that go along with CGM and insulin pump therapy — sensors, infusion sets, reservoirs — can feel overwhelming. That's where a dedicated diabetes supplier like MDS Diabetes can help, ensuring you have everything you need, delivered reliably, so you can focus on living rather than logistics.
While this study was conducted in Belgium, the clinical findings and cost-effectiveness principles apply broadly, and similar analyses in other countries have reached comparable conclusions.
Bottom Line
The t:slim X2 with Control-IQ technology gives adults with Type 1 diabetes nearly 1.6 more quality years of life compared to injections or a standard pump, at a cost that falls well within accepted value-for-money thresholds. Reduced fear of lows adds further everyday benefit. Evidence continues to build that automated insulin delivery is not a luxury — it's a sound medical and economic investment.